[Retracted] Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification

Figure 4

The efficiency of plasma FOXD3-AS1 in cancer diagnosis and SCLC identification. (a)–(g) ROC curves used to validate the discrimination efficiency of plasma FOXD3-AS1 for SCLC vs. HS (a), LUAD vs. HS (b), LUSC vs. HS (c), LC vs. HS (d), SCLC vs. LUAD (e), SCLC vs. LUSC (f), and LUAD vs. LUSC (g).

(a)

(b)

(c)

(d)

(e)

(f)

(g)